UMIN-CTR Clinical Trial

Recruitment status Main results already published
Unique ID issued by UMIN UMIN000046037
Receipt No. R000052547
Scientific Title Evaluation for topical use of ripasudil as ophthalmic solution.
Date of disclosure of the study information 2021/11/11
Last modified on 2021/11/11 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Evaluation for topical use of ripasudil as ophthalmic solution.
Acronym Evaluation for topical use of ripasudil as ophthalmic solution.
Scientific Title Evaluation for topical use of ripasudil as ophthalmic solution.
Scientific Title:Acronym Evaluation for topical use of ripasudil as ophthalmic solution.
Region
Japan

Condition
Condition Glaucoma
Classification by specialty
Ophthalmology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Evaluation for topical use of ripasudil as ophthalmic solution.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes visual acuity, IOP, ECD, CCT, TCT
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
110 years-old >=
Gender Male and Female
Key inclusion criteria Without active ocular surface disease
Key exclusion criteria With active ocular surface disease
Target sample size 26

Research contact person
Name of lead principal investigator
1st name Hisataka
Middle name
Last name Fujimoto
Organization Kawasaki Medical School
Division name Department of Ophthalmology
Zip code 701-0192
Address Matsushima 577, Kurashiki
TEL 0864621111
Email fujimoto-h@med.kawasaki-m.ac.jp

Public contact
Name of contact person
1st name Hisataka
Middle name
Last name Fujimoto
Organization Kawasaki Medical School
Division name Department of Ophthalmology
Zip code 701-0192
Address Matsushima 577, Kurashiki
TEL 0864621111
Homepage URL
Email fujimoto-h@med.kawasaki-m.ac.jp

Sponsor
Institute Kawasaki Medical School
Institute
Department

Funding Source
Organization Charitable Trust Fund for Ophthalmic Research in Commemoration of Santen Pharmaceutical's Founder 2019
Organization
Division
Category of Funding Organization Non profit foundation
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Kawasaki Medical School
Address Matsushima 577, Kurashiki
Tel 0864621111
Email fujimoto-h@med.kawasaki-m.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2021 Year 11 Month 11 Day

Related information
URL releasing protocol https://tvst.arvojournals.org/article.aspx?articleid=2772488
Publication of results Partially published

Result
URL related to results and publications https://tvst.arvojournals.org/article.aspx?articleid=2772488
Number of participants that the trial has enrolled 26
Results The mean endothelial cell density loss 90 to 120 days after surgery, excluding bullous keratopathy patients for whom measurements were not possible was -4.5% in the ripasudil group, which was significantly lower than in control group
Results date posted
2021 Year 11 Month 11 Day
Results Delayed
Results Delay Reason
Date of the first journal publication of results
2021 Year 04 Month 01 Day
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Main results already published
Date of protocol fixation
2019 Year 11 Month 11 Day
Date of IRB
2019 Year 11 Month 11 Day
Anticipated trial start date
2019 Year 11 Month 11 Day
Last follow-up date
2021 Year 01 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Kawasaki Medical School

Management information
Registered date
2021 Year 11 Month 11 Day
Last modified on
2021 Year 11 Month 11 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052547